- Trial phase
- Phase 2b/3
- Time to market
- Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
- Why 4/10
- No specific hard, dated catalyst (PDUFA or pivotal readout date) is scheduled within the next ~12 months. iDose TREX is a mid-stage (Phase 2b/3) program at a company with an already-approved commercial product (iDose TR) and other pipeline assets, so it is not a near-term binary event for the stock.
Monitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.
Price Chart
Executive Summary
iDose TREX is Glaukos' next-generation sustained-release travoprost intracameral implant for glaucoma, designed with nearly double the drug capacity of the already-FDA-approved iDose TR. Glaukos commenced a Phase 2b/3 clinical program in January 2025, and early data from a 10-patient study presented at AGS 2026 showed positive IOP reduction. As a mid-stage pipeline asset at a company with an approved commercial product (iDose TR) and other programs, iDose TREX is not a near-term binary catalyst. The stock trades near its 52-week high with strong analyst support (Strong Buy consensus, ~8% implied upside to mean target), but insider selling and mixed institutional signals warrant caution.
How It Works
iDose TREX is a tiny implant placed inside the eye that continuously releases travoprost, a prostaglandin analog drug that lowers intraocular pressure (eye pressure) in glaucoma patients. It is designed to provide long-duration pressure control from a single administration, reducing the need for daily eye drops. The 'TREX' version holds nearly twice the drug as the already-approved iDose TR, potentially extending the duration of effect.
Trial Status
Glaukos commenced a Phase 2b/3 clinical program for iDose TREX in January 2025. Early data from a 10-patient study presented at the American Glaucoma Society (AGS) meeting in March 2026 showed double-digit IOP reduction. The Phase 2b/3 program is designed to support eventual FDA approval, building on the safety and efficacy data from the first-generation iDose TR product.
The Two-Sided Case
Upcoming Catalysts
- Interim or topline data from the Phase 2b/3 clinical program
- Presentations at major ophthalmology conferences (AAO, AGS)
- iDose TR commercial adoption and revenue growth updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GLAUKOS Corp 8-K GKOS ·Originating report